At a glance
ClinicalIndex Comparison RecordN/ACompleted· 6 enrolled
Drug / intervention
Estrogen suppressiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ovarian Function and Facultative Thermogenesis
In Brief
A clinical study evaluating Estrogen suppression for Obesity. Completed, enrolled 6 participants across 1 site.
Detailed Summary
Menopause is associated with weight gain, but the reasons why are not clear. In this study, the investigators will determine if reducing estrogen levels causes a decrease in the ability of the body to produce heat. If so, this would suggest this is one way that menopause may cause weight gain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedMay 2013
Primary CompletionOct 2015
Study CompletionOct 2016
TodayJul 2026
First PostedMay 3, 2013
Enrollment StartApr 1, 2013
Primary CompletionOct 1, 2015
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.2 years ago
Interventions
Estrogen suppressiondrug
Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function